A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
Player FM - Internet Radio Done Right
Checked 22h ago
Added four years ago
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Similar to The Chain: Protein Engineering Podcast
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
This Week in Microbiology is a podcast about unseen life on Earth hosted by Vincent Racaniello and friends. Following in the path of his successful shows 'This Week in Virology' (TWiV) and 'This Week in Parasitism' (TWiP), Racaniello and guests produce an informal yet informative conversation about microbes which is accessible to everyone, no matter what their science background.
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Unexplainable takes listeners right up to the edge of what we know…and then keeps on going. The Unexplainable team — Noam Hassenfeld, Julia Longoria, Byrd Pinkerton, and Meradith Hoddinott — tackles scientific mysteries, unanswered questions, and everything we learn diving into the unknown. New episodes Mondays and Wednesdays.
…
continue reading
Unseeable forces control human behavior and shape our ideas, beliefs, and assumptions. Invisibilia—Latin for invisible things—fuses narrative storytelling with science that will make you see your own life differently.
…
continue reading
Going Wild with Dr. Rae Wynn Grant is a different kind of nature show about the human drama of saving animals. From a paleoanthropologist who hunts fossils in conflict zones to someone who helped save an endangered species while in prison, in season four we will hear from real-life heroes and nature advocates with widely different expertise and life experiences that led them to be champions for the natural world. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals i ...
…
continue reading
Deep in the back of your mind, you’ve always had the feeling that there’s something strange about reality. There is. Join Robert Lamb and Joe McCormick as they examine neurological quandaries, cosmic mysteries, evolutionary marvels and our transhuman future.
…
continue reading
All In The Mind is ABC RN's weekly podcast looking into the mental universe, the mind, brain and behaviour — everything from addiction to artificial intelligence.
…
continue reading
Science Friction's latest series is: Cooked. We dig into food science pickles. Why are studies showing that ice cream could be good for you? Do we really need as many electrolytes as the internet says? And why are people feeling good on the carnivore diet? Nutrition and food scientist Dr Emma Beckett takes us through what the evidence says about foods like meat, ice cream and potatoes — and unpicks why nutrition studies can be so conflicting and confusing. All six episodes of Cooked are avai ...
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
))
Podcasts Worth a Listen
SPONSORED
W
We Have The Receipts
1 Battle Camp: Final 5 Episodes with Dana Moon + Interview with the Winner! 1:03:29
1:03:29 
Play Later 
Play Later 
Lists 
Like 
Liked1:03:29
Play Later
Play Later
Lists
Like
LikedFinally, we find out who is unbeatable, unhateable, and unbreakable in the final five episodes of Battle Camp Season One. Host Chris Burns is joined by the multi-talented comedian Dana Moon to relive the cockroach mac & cheese, Trey’s drag debut, and the final wheel spin. The Season One Winner joins Chris to debrief on strategy and dish on game play. Leave us a voice message at www.speakpipe.com/WeHaveTheReceipts Text us at (929) 487-3621 DM Chris @FatCarrieBradshaw on Instagram Follow We Have The Receipts wherever you listen, so you never miss an episode. Listen to more from Netflix Podcasts.…
Episode: 47 - Bonus Episode with PEGS Young Scientist Keynote Dr. Andrew Anzalone on Engineering Prime Editor Proteins for Therapeutic Applications
Manage episode 359180828 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Dr. Andrew Anzalone, head of the Prime Editing Platform and scientific co-founder at Prime Medicine, is the winner of the PEGS Boston 2023 Young Scientist Keynote. He was invited to sit down with Brandon DeKosky, assistant professor of chemical engineering at MIT, to discuss prime editing and its precision in treating inherited genetic mutations. Anzalone outlines the next generation tool’s advantages over traditional CRISPR methods and the mechanism creating fewer gene editing errors. He also discusses his clinical training and background, the ongoing projects at Prime Medicine in engineering proteins for cell-based therapeutics, and his thoughts on the current challenges and future developments in gene editing and precision medicine.
Links from this episode:
Prime Medicine
PEGS Boston Conference & Expo
75 episodes
ShareManage episode 359180828 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Dr. Andrew Anzalone, head of the Prime Editing Platform and scientific co-founder at Prime Medicine, is the winner of the PEGS Boston 2023 Young Scientist Keynote. He was invited to sit down with Brandon DeKosky, assistant professor of chemical engineering at MIT, to discuss prime editing and its precision in treating inherited genetic mutations. Anzalone outlines the next generation tool’s advantages over traditional CRISPR methods and the mechanism creating fewer gene editing errors. He also discusses his clinical training and background, the ongoing projects at Prime Medicine in engineering proteins for cell-based therapeutics, and his thoughts on the current challenges and future developments in gene editing and precision medicine.
Links from this episode:
Prime Medicine
PEGS Boston Conference & Expo
75 episodes
All episodes
×
T
The Chain: Protein Engineering Podcast
1 Episode: 72 - Pamela Barney on HR Lessons to Meet the Needs of Biotech 35:23
35:23 Play Later Play Later Lists Like Liked35:23
Play Later Play Later Lists Like LikedIn this episode of The Chain, host Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC, talks with Pamela Barney, former associate director of HR, AbbVie, about her career within biotech/pharma organizations and some key lessons learned, such as taking advantage of your contacts and network, managing diverse workforces, and HR’s role in creating an engaged team. Barney also discusses why she entered the HR field and the challenges of culture changes when transitioning from a small organization to a large company. AbbVie: https://www.abbvie.com/…
T
The Chain: Protein Engineering Podcast
1 PEGS Young Scientist Keynote Jessica Stark on the Role of Glycans in Cancer Research 28:38
28:38 Play Later Play Later Lists Like Liked28:38
Play Later Play Later Lists Like LikedIn this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about glycans and why they are important in cancer research. Stark discusses how she became interested in immunology, what her PhD and post-doctoral training was like, her thoughts on singlets operating as part of a network of checkpoint molecules, and what’s currently going on in glycobiology. She also talks about her keynote presentation at PEGS 2025 and what her new lab is working on. LINKS: MIT Department of Chemical Engineering MIT Department of Biological Engineering MIT…
T
The Chain: Protein Engineering Podcast
1 Episode: 70 - Views on Machine Learning and AI in the Antibody and Protein Engineering Space 49:36
49:36 Play Later Play Later Lists Like Liked49:36
Play Later Play Later Lists Like LikedMarch 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future.…
T
The Chain: Protein Engineering Podcast
1 Episode: 69 - Conversation with Sir Greg Winter on the 50th Anniversary of the Milstein and Köhler Paper 50:36
50:36 Play Later Play Later Lists Like Liked50:36
Play Later Play Later Lists Like LikedFebruary 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma technology, which paved the way for monoclonal antibodies. Ralph Minter, Biotech CSO/CTO, discusses this important milestone with a true pioneer in the field, Sir Greg Winter, Nobel Laureate and one of the key figures in the development of therapeutic antibodies.…
T
The Chain: Protein Engineering Podcast
1 Episode: 68 - Changing the Game of Protein-Protein Interactions With Randolph Lopez 46:00
46:00 Play Later Play Later Lists Like Liked46:00
Play Later Play Later Lists Like LikedIn this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez also discusses how this affects the potential of AI and ML. LINKS: Bionavigen A-Alpha Bio Specifica…
T
The Chain: Protein Engineering Podcast
1 Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field 42:34
42:34 Play Later Play Later Lists Like Liked42:34
Play Later Play Later Lists Like LikedNovember 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs, and where he sees ADCs heading in the future. LINKS: Bionavigen NEXT Oncology…
T
The Chain: Protein Engineering Podcast
1 Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond 39:43
39:43 Play Later Play Later Lists Like Liked39:43
Play Later Play Later Lists Like LikedOctober 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more. LINKS: Bionavigen ImmunoGen…
T
The Chain: Protein Engineering Podcast
1 Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More 31:55
31:55 Play Later Play Later Lists Like Liked31:55
Play Later Play Later Lists Like LikedSeptember 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, of Tariq Ghayur Consulting, LLC and Entrepreneur in Residence, FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from small molecules to biologics, and the major differences between doing a postdoc in academia versus in the industry.…
T
The Chain: Protein Engineering Podcast
1 Episode: 64 - Peyton Greenside on AI’s Role in Antibody Engineering, Optimization, and More 32:31
32:31 Play Later Play Later Lists Like Liked32:31
Play Later Play Later Lists Like LikedIn this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such as GPCRs, and certain properties that AI can optimize better.…
T
The Chain: Protein Engineering Podcast
1 Episode: 63 - Discussing Protein Signaling and Structural Biology With Andrew Kruse 38:18
38:18 Play Later Play Later Lists Like Liked38:18
Play Later Play Later Lists Like LikedIn this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to resolve, as well as the tools they use to work out the dynamics of structures. He also shares the findings in signaling receptors and biology that he’s most excited about, recent advancements that have caught his attention, and the new directions for him and his lab.…
T
The Chain: Protein Engineering Podcast
1 Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype 1:03:57
1:03:57 Play Later Play Later Lists Like Liked1:03:57
Play Later Play Later Lists Like Likedhis special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo Nordisk take on where AI/ML has the biggest impact, what the hype is in the use of AI/ML in antibody discovery, how new AI/ML methods are being benchmarked against traditional discovery methods, and what controls should be used in an AI/ML discovery or optimization campaign.…
T
The Chain: Protein Engineering Podcast
1 Episode: 61 - Tomoyuki Igawa Discusses Leadership and His Experiences in Discovery and Development 55:04
55:04 Play Later Play Later Lists Like Liked55:04
Play Later Play Later Lists Like LikedIn this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, speaks with Tomoyuki Igawa, PhD, chief executive officer, Chugai Pharmabody Research in Singapore, about his 20+ years of experience in drug discovery and development. Igawa possesses a unique perspective that has allowed him and his team to develop innovative concepts, such as recycling sweeping antibodies and bispecific platforms. He discusses how the discovery and development organizations work together to provide a steady supply of products, how he builds the right team when starting a new project, and how to keep team members engaged and motivated. He also offers advice for young scientists on the importance of enjoying their work and how to maintain work-life balance.…
T
The Chain: Protein Engineering Podcast
1 Episode: 60 - Lesley Millar-Nicholson on Technology Licensing, Navigating Patents, and Building Teams 48:14
48:14 Play Later Play Later Lists Like Liked48:14
Play Later Play Later Lists Like LikedThis month The Chain shares a recent episode of the Lab Rats to Unicorns podcast. Lab Rats to Unicorns, hosted by John Flavin, aims to demystify the process of creating a great company in the life sciences, biotech, medtech, clean energy, and beyond. In this episode, Flavin speaks with Lesley Millar-Nicholson, executive director of MIT’s Technology Licensing Office (TLO). Millar-Nicholson discusses the role of the TLO, what happens after a patent is filed and licensed to a company or start-up, how she got her start in the field, and her journey from Scotland to the U.S. She also delves into finding the right people for the best team, the importance of a diverse workforce and awareness, and being around science as a non-scientist.…
T
The Chain: Protein Engineering Podcast
1 Episode: 59 - Gabriel Rocklin on Protein Biophysics and Protein Design 33:10
33:10 Play Later Play Later Lists Like Liked33:10
Play Later Play Later Lists Like LikedIn this month’s episode of The Chain, host Ben Hackel, professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Gabriel Rocklin, assistant professor of Pharmacology at Northwestern University, about two recently published papers from Rocklin’s lab: one on advancing the ability to design challenging typologies and one on developing and leveraging a new technique on high-throughput protein biophysics. Rocklin shares the journey from ideation to realization of the research process, the inspiration that motivated the work, and interesting results and technological advancements discovered along the way. He also talks about the opportunities emerging from his team’s research and the challenges that still need overcoming, as well as offers advice for future scientists interested in protein biophysics.…
T
The Chain: Protein Engineering Podcast
1 Episode: 58 - Janine Schuurman Reflects on the Key Lessons and Accomplishments of Her 20-Year Career 55:05
55:05 Play Later Play Later Lists Like Liked55:05
Play Later Play Later Lists Like LikedHow does one maintain innovation in the antibody industry? In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, talks with Janine Schuurman, PhD, president of The Antibody Society, independent biotech consultant and founder of Lust for Life Sciences, about her inspiration to get into antibody engineering, her impressive career at Genmab, advice for a productive work environment, and her current work. Dr. Schuurman also shares insights on staying innovative, how to deal with the challenges of the industry, why young scientists should not be afraid to fail, as well as her plans as the new president of The Antibody Society. Links: Lust for Life Sciences: https://www.lustforlifescience.com/ The Antibody Society: https://www.antibodysociety.org/ FairJourney Biologics: https://fjbio.com/…
T
The Chain: Protein Engineering Podcast
1 Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D. 33:06
33:06 Play Later Play Later Lists Like Liked33:06
Play Later Play Later Lists Like LikedBispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.…
T
The Chain: Protein Engineering Podcast
1 Episode: 56 - Thomas Sakmar on the Golden Age for the Application of Biologics to GPCR Pharmacology 44:38
44:38 Play Later Play Later Lists Like Liked44:38
Play Later Play Later Lists Like LikedWhat can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at GlaxoSmithKline, speaks with Thomas P. Sakmar, MD, Professor of Chemical Biology at Rockefeller University, about the history of GPCRs and various subunits, his early work with rhodopsin, and the impact of crystallography and structural work. He also shares how he got started with molecular biology training, as well as his thoughts on the state-of-the art for both biologics and small molecules in drug discovery. LINKS: Rockefeller University: https://www.rockefeller.edu GlaxoSmithKline: https://www.gsk.com/en-gb/…
T
The Chain: Protein Engineering Podcast
1 Episode: 55 - Tala Fakhouri Discusses AI/ML for Biologics Drug Discovery & Development 33:27
33:27 Play Later Play Later Lists Like Liked33:27
Play Later Play Later Lists Like LikedIn this episode of The Chain, Richard Bonneau, PhD, and Marcel Hop, PhD, of Genentech interview Tala Fakhouri, PhD, of the FDA on her thoughts on the discussion paper, “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biologic Products” and the evolving role of AI/ML to create models and inform decisions in biopharmaceutical development and regulatory submissions. Dr. Fakhouri also discusses the impact AI/ML models could have on clinical trial conduct, patient enrollment, patient selection, and data interpretation. She also talks about the next steps to get the right processes in place and why transparency is important to establish trust with patients about AI/ML tools.…
T
The Chain: Protein Engineering Podcast
1 Episode: 54 - Enkelejda Miho on the Current State of AI: Drug Development, Research, and the Future 29:20
29:20 Play Later Play Later Lists Like Liked29:20
Play Later Play Later Lists Like LikedWith the whirlwind development of AI, it can be difficult to keep track of its uses in both research and the market. In this episode of The Chain podcast, host Ben Hackel, Professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Enkelejda “Ledi” Miho, Professor of Digital Life Sciences at the University of Applied Sciences Northwestern Switzerland FHNW, who breaks down the current state of AI and its role in drug development. She talks about the opportunities of AI and drug discovery and how digital biomarkers and molecular data are helping with personalized medicine. Miho also discusses the challenges of advancing AI, why having an “adisciplinary” approach is the key to assembling the right team, and how to design studies to be as broadly robust as possible, as well as the advancements of her and her team’s own research.…
T
The Chain: Protein Engineering Podcast
1 Episode: 53 - Jonathan Sockolosky on Breaking Into Biotech and Making Real Progress in Ovarian Cancer Treatments 26:48
26:48 Play Later Play Later Lists Like Liked26:48
Play Later Play Later Lists Like LikedWhat is the first step of getting into biotech? How do you make real progress in research? In honor of Ovarian Cancer Awareness Month, host Nimish Gera discusses these topics and more with Jonathan Sockolosky, PhD, Director of CSO Partner Team at Curie.Bio, in this special episode of The Chain. Jonathan details how he got started in biotech, what inspires him to keep going, his personal interests in ovarian cancer treatments, and what he does to raise funds to further ovarian cancer research. Jonathan also offers advice on how others can get involved in causes they are passionate about and how to give back to the community, as well as the progress that has been made in ovarian cancer therapy. Links from this episode: Curie.Bio Mythic Therapeutics…
T
The Chain: Protein Engineering Podcast
1 Episode 52: Entrepreneurship in Immunotherapy: Capstan’s Adrian Bot on Teambuilding 23:31
23:31 Play Later Play Later Lists Like Liked23:31
Play Later Play Later Lists Like LikedIn this episode of The Chain, Brandon Dekosky, Associate Professor at MIT, speaks with Adrian Bot, Founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, about his experiences in leadership roles, his scientific journey, and how he started work on immunotherapy for cancer. Bot also shares what it's like to be a “serial scientific entrepreneur” and the importance of networking to assemble a team that shares mutual interests, as well as how to motivate young scientists and researchers coming into the biotech industry. Finally, he discusses why he finds flat organizational structures with smaller teams more effective and what he does to maintain innovation.…
T
The Chain: Protein Engineering Podcast
1 Episode: 51 - Setting the Right Strategy to Drive Engineering Parameters for Solid Tumor-Targeting T Cell-Engagers 53:45
53:45 Play Later Play Later Lists Like Liked53:45
Play Later Play Later Lists Like LikedIn this special episode of The Chain, G. Jonah Rainey, Senior Director of Protein Engineering at Eli Lilly and Company, hosts a panel at PEGS 2023 to discuss strategies to engineer parameters for solid tumor-targeting T-cell-engagers. Guests Stephen J. Demarest from Tentarix Biotherapeutics, Michelle Morrow from F-Star Therapeutics, Inc., and Dario Neri from Philogen provide their insights and experiences on navigating challenges, researching treatments, and the positives and negatives of certain targeting strategies. They also answer questions from the audience and share their perspectives on the future of tumor-targeting and what technology can do to help with developing effective cures. Links from this episode: PEGS Boston Conference & Expo Engineering Bispecific Antibodies Eli Lilly and Company Tentatrix Biotherapeutics F-Star Therapeutics, Inc. Philogen…
T
The Chain: Protein Engineering Podcast
1 Episode: 50 - Pivoting Research with Antibody Drug Conjugates 31:20
31:20 Play Later Play Later Lists Like Liked31:20
Play Later Play Later Lists Like LikedIn this month’s episode of The Chain, Greg M. Thurber, associate professor of chemical engineering and biomedical engineering at the University of Michigan, sits with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to talk about the development of antibody drug conjugates (ADCs). Thurber details the history of ADCs and the skepticism facing the field during the mid-2010s, despite showing great promise in anticancer treatment. He also discusses how recent FDA approvals and breakthroughs have reignited interest and pivoted research toward designing more successful ADCs. Finally, he shares his thoughts on the exciting developments in the field in the next few years, including how ADCs could play a key role in polytherapy.…
T
The Chain: Protein Engineering Podcast
1 Episode: 49 - Building a Next Generation Bioproduction Platform 23:30
23:30 Play Later Play Later Lists Like Liked23:30
Play Later Play Later Lists Like LikedKyron.Bio is revolutionizing drug production with its Next Generation Bioproduction Platform that will make the production of therapeutics easier, cheaper and faster. Voldborg and McLaughlin talk about their shared vision for using synthetic biology to improve the production of therapeutic proteins. Kyron.Bio: https://kyron.bio/…
T
The Chain: Protein Engineering Podcast
1 Episode: 48 - A Conversation with Peter Tessier: Classifying Antibodies to Assess Biologics Developability Features Early in the Discovery Process 48:01
48:01 Play Later Play Later Lists Like Liked48:01
Play Later Play Later Lists Like LikedIn this month’s episode of the Chain, guest Peter Tessier, Albert M. Mattocks pharmaceutical sciences and chemical engineering professor at the University of Michigan, speaks with moderator Tariq Ghayur, scientific advisor and entrepreneur in residence at FairJourney Biologics, about expediting the developability of antibodies. He discusses the characteristics that best predict a molecule’s drug-like properties, the different assays used for various intended outcomes, and why every scientist must assess the “greatest potential impact” before embarking on a new experiment. Tessier also talks about the core traditions that help him lead students in the lab while fostering a learning environment of ownership, integrity, and self-motivation. Last, he shares his predictions on how computational data will advance antibody discovery and developability in the future.…
T
The Chain: Protein Engineering Podcast
1 Episode: 47 - Bonus Episode with PEGS Young Scientist Keynote Dr. Andrew Anzalone on Engineering Prime Editor Proteins for Therapeutic Applications 40:43
40:43 Play Later Play Later Lists Like Liked40:43
Play Later Play Later Lists Like LikedDr. Andrew Anzalone, head of the Prime Editing Platform and scientific co-founder at Prime Medicine, is the winner of the PEGS Boston 2023 Young Scientist Keynote. He was invited to sit down with Brandon DeKosky, assistant professor of chemical engineering at MIT, to discuss prime editing and its precision in treating inherited genetic mutations. Anzalone outlines the next generation tool’s advantages over traditional CRISPR methods and the mechanism creating fewer gene editing errors. He also discusses his clinical training and background, the ongoing projects at Prime Medicine in engineering proteins for cell-based therapeutics, and his thoughts on the current challenges and future developments in gene editing and precision medicine. Links from this episode: Prime Medicine PEGS Boston Conference & Expo…
T
The Chain: Protein Engineering Podcast
1 Episode: 46 - Leveraging Albumin and IgG FcRn-Mediated Regulation in Therapeutic Development 36:20
36:20 Play Later Play Later Lists Like Liked36:20
Play Later Play Later Lists Like LikedJan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hospital, has spent nearly two decades studying neonatal Fc receptors (FcRns) and their interactions with prominent blood proteins albumin and IgG. He sits down with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to discuss the unique properties of FcRn and how it can be leveraged for novel therapeutic development. Additionally, Andersen details the mechanics of FcRn binding, why it prolongs albumin and IgG half-lives, and notable FcRn technological advancements and research findings in animal and human models. He also talks about engineering blood proteins for optimal function and launching his new venture, Authera, the preclinical stage biotech company using an FcRn-centered platform to study the receptor’s versatility across multiple cell types. Links from this episode: University of Oslo Mythic Therapeutics Authera…
T
The Chain: Protein Engineering Podcast
1 Episode: 45 - Advances in Targeted Protein Degradation 30:16
30:16 Play Later Play Later Lists Like Liked30:16
Play Later Play Later Lists Like LikedIn this month’s episode of the Chain, Jim Wells, professor of pharmaceutical chemistry and cellular and molecular pharmacology at the University of California, San Francisco, sits down with moderator Ben Hackel, associate professor of chemical engineering and materials science at the University of Minnesota, to discuss Wells’ work in advancing targeted protein degradation. Wells outlines the key design elements of targeted protein degraders and their general mechanism of action, how his lab developed antibody-based PROTACs—also known as AbTACs—to target extracellular proteins, and the innovative work from industry leaders that inspired his lab’s discoveries. He also speaks about the lingering questions driving ongoing and future projects, the challenges facing the protein degradation space, and why he considers himself a “pirate of biology” rather than an inventor. Links from this episode: University of California, San Francisco University of Minnesota Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 PEGSBoston Conference and Expo…
T
The Chain: Protein Engineering Podcast
1 Episode 44: Structure Forward: Using Structural Biology Pipelines to Achieve Favorable Antibody Responses 31:46
31:46 Play Later Play Later Lists Like Liked31:46
Play Later Play Later Lists Like LikedOver the last two decades, cryogenic electron microscopy (cryo-EM) has transformed from what Dr. Andrew Ward calls the “outcast of structural biology” to one of the most promising technologies in the field. Ward, professor of integrative structural and computational biology at Scripps Research Institute, speaks with moderator Brandon DeKosky, assistant professor of chemical engineering at the Massachusetts Institute of Technology, about the evolution of cryo-EM and how its direct detector transformative technology enables scientists to craft favorable antibody responses. Ward also talks about cryo-EM’s technological advantages when working with proteins, sterilizing immunity, and designing accurate structural biology pipelines that lead to next-generation vaccines. Finally, Ward offers his predictions about the immunological breakthroughs he thinks structural biologists will accomplish in the very near future. Links from this episode: Scripps Research Institute PepTalk Conference Discovery on Target Conference…
T
The Chain: Protein Engineering Podcast
1 Episode: 43 - Evolution of Antibody Technologies 28:26
28:26 Play Later Play Later Lists Like Liked28:26
Play Later Play Later Lists Like LikedDame Jane Osbourn, chief scientific officer at Alchemab Therapeutics, speaks with Ahuva Nissim, antibody and therapeutic engineering professor at Queen Mary University of London William Harvey Research Institute, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent protective antibodies. Osbourn talks about the most inspiring mentors of her career, her interest in immunological resiliency, the importance of studying neurodegenerative diseases, and her drug discovery work at Alchemab Therapeutics. Finally, she talks about the technological advancements she hopes will move precision medicine forward in the near and distant future.…
T
The Chain: Protein Engineering Podcast
1 Episode: 42 - Machine Learning Informatics for Antibody Discovery 36:04
36:04 Play Later Play Later Lists Like Liked36:04
Play Later Play Later Lists Like LikedCharlotte Deane, professor of structural bioinformatics at the University of Oxford and upcoming speaker at the 14th Annual PEGS Europe Conference in Barcelona, joins moderator Brandon DeKosky, assistant professor of chemical engineering at the Massachusetts Institute of Technology, to discuss the use of machine learning in antibody structure prediction. In this episode, Deane talks about her lab's AI tools for high-throughput prediction pipelines and why collecting general antibody property data will produce better models. She also speaks about the importance of using and building publicly available data sets and her thoughts on what it will take to finally generate a complete antibody design from a computer. Links from this episode: University of Oxford Department of Statistics SAbDAb: The Structural Antibody Database PEGS Europe The Critical Assessment of protein Structure Prediction (CASP)…
T
The Chain: Protein Engineering Podcast
1 Episode: 41 - Introduction and Evolution of the Antibody Patent Landscape 20:30
20:30 Play Later Play Later Lists Like Liked20:30
Play Later Play Later Lists Like LikedAfter over 25 years as an intellectual property (IP) attorney, Jane Remillard, Nelson Mullins patents and biotechnology IP senior partner, is well-versed in navigating drug development and antibody patent law. In this episode, Remillard speaks with moderator Nimish Gera, Mythic Therapeutics vice president of biologics, about the intersection between science and law, the primary steps recommended to patent a scientific discovery, and how the antibody IP landscape has evolved in recent years. She also talks about the importance of implementing a strategy regarding the number and types of antibody patents filed, her advice to anyone considering a career in IP law, and what to expect from the industry moving forward. Links from this episode: Nelson Mullins Mythic Therapeutics…
T
The Chain: Protein Engineering Podcast
1 Episode 40: Exploring Developability Concepts with Bispecific Antibodies 15:53
15:53 Play Later Play Later Lists Like Liked15:53
Play Later Play Later Lists Like LikedDr. Nimish Gera, Head of Biologics at Mythic Therapeutics, sits down with Christina Lingham, Executive Director of Conferences and Fellow at Cambridge Healthtech Institute, in this Episode of the Chain to talk about how the developability of bispecific antibodies topic came about, how the field is changing, new bispecific molecules coming through the pipeline, and his expectations for the future.…
T
The Chain: Protein Engineering Podcast
1 Episode 39: René Hoet on Antibody Discovery and Following Your Heart 20:29
20:29 Play Later Play Later Lists Like Liked20:29
Play Later Play Later Lists Like LikedRene Hoet is working for over 20 years in Biotech and Pharma Industry focusing on Antibody Research and development. Since April 1 2021 Rene works as Chief Scientific Officer at Montis Biosciences, Leuven, Belgium to develop the next generation Immuno-Oncology drugs using a novel approach interfering in the Tumor Endothelial Cell and Perivascular Macrophage Interactions to restore a immunocompetent tumor microenvironment. From Oct. 2018 till 26 March 2021 Rene worked as Chief Scientific Officer at Imcheck Therapeutics (Marseille, France) reporting to the CEO where he built up a successful mAb research & development group on first in class mAbs (and bispecifics) in immune-oncology targeting butyrophilins and immune modulating gammadelta T cell and macrophage subsets. In Nov. 2019, Rene together with the CEO raised 48 M euro series B investment and moved ICT01 an antibody to BTN3A1, the first activating gammadelta T cell mAb, from preclinical stage into the clinic (start clinical trial March 2020). From 2010-2018 Rene worked for Bayer AG as Vice President Biologics Research (Cologne, Germany), part of the Biologics Research & Development leadership team at Bayer reporting to the Sr. VP. Biologics Research & Development. His group was responsible for Antibody Discovery and Optimization for all therapeutic areas in Bayer (incl. Cardiovascular Diseases, Oncology, Gynecology,Hematology and Autoimmunity) and during this period a number of antibodies from Bayer´s internal pipeline entered into the clinic. Anetumab (Mesothelin-ADC), FXIa (phase II), C4.4.a-ADC, FGFR2-ADC, PRLR, TIFPa, CD22-TTC, CEACAM6 (all phase I). In addition Rene was appointed in 2012 to extraordinary Prof. Biopharmaceutics at the University of Maastricht, The Netherlands to guide researchers to use antibodies to Bridge the Gap between academic research and pharma applications. Between 2008-2010 Rene worked at Genmab as Sr. Director Research and was heading up Product Related Research, Scientific Communication & Translational Research. His team was driving new Antibody Discovery Programs and was also actively supporting Clinical Antibody Programs of Ofatumumab (CD20) (FDA approved 2009) and Daratumumab (CD38) (FDA approved 2015). From 1997-2008 Rene had various positions at Dyax and became V.P. Research and Operational Manager of Dyax sa. Rene and his team were driving internal Antibody Lead Discovery (in Dyax Liege Belgium and Cambridge US) as well as external collaborations and supporting out-licensing of Dyax antibody phage libraries. From the antibody phage libraries he developed at Dyax now 4 antibodies have been approved Ramucirumab (KDR), Lilly, 2014, Necitumumab (EGFR), Lilly, 2015, Avelumab (PDL-1) EMD Serono/Pfizer, 2017, and lanadelumab (kallikrein), Shire, 2018). In addition over 10 antibodies from this mAb library from various companies are still in clinical trial. Rene obtained his PhD at the Un. Nijmegen, the Netherlands and performed a post-doctoral study at the Un. Cambridge U.K.with Prof. G. Winter (nobel prize winner 2018). He contributed to over 40 scientific papers and is inventor on 20 patent /patent applications.…
T
The Chain: Protein Engineering Podcast
1 Episode 38: Pivoting to Meet Protein Purification Needs with TriAltus 25:32
25:32 Play Later Play Later Lists Like Liked25:32
Play Later Play Later Lists Like LikedA University of Alabama Birmingham researcher was frustrated with inconsistent solutions and processes for purifying unique proteins and set out to develop a new approach for high throughput protein purification. Thus was the seed idea for TriAltus Bioscience, which aims to bring protein purification technology from the research bench to the production environment. The Chain spoke with Bob Shufflebarger, CEO of TriAltus to give the background story and insights into future developments. TriAltus lab manager Naomi Logsdon joined the conversation to share her scientific background and passion for discovery, plus explain the novel technology used in TriAltus purification. Naomi Logsdon, Lab Manager, TriAltus Bioscience Naomi Logsdon is a molecular biologist and laboratory manager with over 30 years of experience and an outstanding record of scientific research in both academic and industrial settings. She is a co-author on more than 40 peer-reviewed publications and holds two gene patents. Logsdon graduated from Rice University cum laude with a B.A. in Biology. She began her research as an undergraduate assistant and was co-author on four research publications studying oxygen radical toxicity. Cell biology and cancer were the focus at subsequent positions at Baylor College of Medicine, DuPont Merck Pharmaceuticals, and the University of Delaware. Protein expression and purification became an area of interest at AstraZeneca Pharmaceuticals, where she evaluated several expression systems for use in high-throughput screening. She also cloned two novel potassium channels as potential drug targets. She later joined the University of Alabama at Birmingham (UAB) at the Center for Biological Sciences and Engineering, where her protein expression and purification skills were applied to crystallographic studies of interleukins. She held managerial and technical positions in several other labs at UAB prior to joining TriAltus in 2019. Bob Shufflebarger, CEO, TriAltus Bioscience Bob Shufflebarger is a life sciences industry veteran. He has more than 25 years’ experience in various facets of life science and technology businesses, from his earliest years working at the scientific bench to experience directing operations, finance, and marketing; developing turnaround strategies, and initiating and completing licensing deals. Shufflebarger founded TriAltus Bioscience in 2017 to commercialize novel protein purification technology from the University of Alabama at Birmingham. Prior to TriAltus, Shufflebarger worked at Atherotech Diagnostics for 16 years, where he held positions within the company including Finance Director, Vice President of Operations, and Chief Operating Officer. As COO he initiated a business pivot that led to revenue turnaround and substantial growth, culminating in sale to a Private Equity firm and eventual growth to more than $100M in annual revenue. Shufflebarger earned a B.S. in Chemistry from Birmingham-Southern College and an MBA from Duke University. He was a member of the Board of Directors of the Birmingham Venture Club for 10 years, and served Board President in 2015 and 2016. He chaired the American Heart Association’s Heart Walk in 2015 and is a 2019 graduate of Leadership Birmingham.…
T
The Chain: Protein Engineering Podcast
1 Episode 37: Flashback Friday: COVID-19 Science-Sequence-Structure for Pandemic Preparedness 21:18
21:18 Play Later Play Later Lists Like Liked21:18
Play Later Play Later Lists Like LikedThe Chain looks back to earlier this year when researchers virtually convened on the one-year anniversary of the first documented case of COVID-19 in the United States. This episode brings you a panel discussion from PepTalk Protein Science and Production Week, moderated by Karla Satchell, PhD, Professor of Microbiology and Co-Director of the Center for Structural Genomics of Infectious Diseases at Northwestern University. The panel discusses the role of data integration for the rapid R&D of therapeutics and vaccines, the immediate challenges in the new year – as the Delta variant spreads this summer in the United States -- and how we can transform nearsighted lessons learned into a farsighted vision of pandemic preparedness. Moderator: Karla Satchell, PhD, Professor, Microbiology; Principal Investigator and Co-Director, Center for Structural Genomics of Infectious Diseases, Northwestern University Panelists: William Gillette, PhD, Principal Scientist, Protein Expression Laboratory, Leidos Biomedical Research Arvind Ramanathan, PhD, Computational Biologist, Argonne National Laboratory Erica Ollmann Saphire, PhD, Professor, La Jolla Institute for Immunology Anupam Singhal, PhD, Senior Product Manager, Antibody Discovery, Marketing, Berkeley Lights, Inc.…
T
The Chain: Protein Engineering Podcast
1 Episode 36: Quality Control from Molecule to Organization 27:03
27:03 Play Later Play Later Lists Like Liked27:03
Play Later Play Later Lists Like LikedNancy Sajjadi joins The Chain to share her quality control knowledge and experience of adopting a quality-by-design approach for assays. We discuss how the focus of her QC work has changed through the years, and what kind of challenges she foresees as the cell and gene therapy fields move forward. Ms. Sajjadi talks about consulting with clients who are developing cutting edge therapies and explains her approach of creating a “culture of quality” within scientific organizations to lead to more successful outcomes. Nancy Sajjadi, Independent Quality Consultant Nancy Sajjadi, M.Sc. is an independent quality consultant with over 30 years of experience in biopharmaceutical product development. She began her career as a bench scientist doing malaria vaccine research before turning to development of cell and gene using therapy retroviral vectors for infectious disease, cancer, and cell therapy applications. Her responsibilities there included research, development, and quality control. She left her position as Director of QC at Chiron Technologies Center for Gene Therapy, in 2000 and to start a consulting business. She has provided services to biopharmaceutical companies, contract laboratories, non-profit organizations, universities, and US government agencies. She has assisted clients in the development, implementation, and improvement of quality programs for a range of biopharmaceutical products in early phase development. She also has provided technical expertise in assay development, qualification, and validation. Ms. Sajjadi has authored several articles pertaining to bioassays and viral gene therapy, has served on 5 advisory panels for the United States Pharmacopeia (USP) and teaches introductory courses in bioassay design, development, and validation for non-statisticians.…
T
The Chain: Protein Engineering Podcast
1 Episode 35: NK Cells and the Science of Innate Immunity w/ Éric Vivier 37:16
37:16 Play Later Play Later Lists Like Liked37:16
Play Later Play Later Lists Like LikedIn this episode, Dr. Willem Overwijk returns for a conversation with Dr. Éric Vivier. Dr. Vivier is a professor of immunology at Aix-Marseille and a hospital practitioner at Marseille Public University Hospital. Éric Vivier is also the Chief Scientific Officer at Innate Pharma, a clinical-stage biotech company that creates novel antibodies that activate the immune system to treat patients with cancer. They discuss Dr. Vivier’s scientific background, the importance and the potential of Natural Killer cells, and the next wave of immunotherapy.…
T
The Chain: Protein Engineering Podcast
1 Episode 34: Antibody and Vaccine Development for COVID-19 – Panel Discussion 40:56
40:56 Play Later Play Later Lists Like Liked40:56
Play Later Play Later Lists Like LikedThis episode of The Chain features a live panel discussion moderated by Erica Ollmann Saphire, PhD of La Jolla Institute for Immunology. Expert panelists from academia and government assess the COVID-19 antibody and vaccine development thus far, including what did and did not go well during the pandemic. They also look towards the future and the role mRNA vaccines may play for diseases like influenza, what we learned about the United States’ ability to manufacture during surge production, and what infrastructure is still needed to fight both the current crisis and future outbreaks. Erica Ollmann Saphire, PhD, Professor, La Jolla Institute for Immunology Peter Hotez, MD, PhD, FASTMH, FAAP, Dean, National School of Tropical Medicine; Professor, Departments of Pediatrics, Molecular Virology & Microbiology; Co-Head, Section of Pediatric Tropical Medicine; Health Policy Scholar, Baylor College of Medicine Lakshmi Krishnan, PhD, Vice-President, Life Sciences, National Research Council Canada, Government of Canada Peter W. Marks, MD, PhD, Director, FDA CBER…
T
The Chain: Protein Engineering Podcast
1 Episode 33: Tackling COVID-19 Drug Discovery with Structural Genomics 16:51
16:51 Play Later Play Later Lists Like Liked16:51
Play Later Play Later Lists Like LikedThe Center for Structural Genomics of Infectious Diseases at Northwestern University was prepared for COVID-19 long before the United States economy shut down. Now over a year since COVID-19 was first recorded in the U.S., co-director Dr. Karla Satchell speaks with The Chain about the role of structural genomics in preparing for disease outbreak and response. Karla Satchell, PhD, Professor, Microbiology; Principal Investigator and Co-Director, Center for Structural Genomics of Infectious Diseases, Northwestern University Dr. Karla Satchell is a Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine since 2000. She is also the Principal Investigator for the NIAID-funded Center for Structural Genomics of Infectious Diseases, a multi-site center in high-throughput structure determination for microbial pathogens. In 2020, the Center dedicated significant resources to structural biology of SARS-CoV-2, including efforts to provide structural biology data to support development of novel drugs, vaccines, and therapeutics. Across all areas of research, she has published more than 100 research articles. She has also been elected as a Fellow for the American Academy of Microbiology and the American Association for the Advancement of Science.…
T
The Chain: Protein Engineering Podcast
1 Episode 32: Young Scientist Spotlight: Cryo-EM to Uncover Structures of Coronavirus Spike Glycoproteins 13:22
13:22 Play Later Play Later Lists Like Liked13:22
Play Later Play Later Lists Like LikedLinoleic acid is an essential free fatty acid in the human body and its metabolic pathway is central to immune regulation and inflammation – which are also key symptoms in COVID-19. Using cryo-electron microscopy, Christine Toelzer’s research identified linoleic acid bound to a hydrophobic pocket of the SARS-CoV-2 glycoprotein. Christine shares her thoughts on how these findings will contribute to the fight against COVID-19 and how her lab work has been altered by the pandemic. Christine also discusses the future of other young scientists coming up in the protein science space. Christine Toelzer is currently a Research Associate at the University of Bristol. After a M.Sc. in biology and an additional M.Sc. in physics she continued with PhD work in biochemistry at the University of Cologne. Her research has always focused on structure function relationships, starting with structure determination of biotechnologically important proteins by x-ray crystallography, magnetic structure determination of inorganic compounds by neutron diffraction and recently using electron cryo-microscopy to obtain the structure of large protein complexes involved in transcription and diseases. In the last year (2020) she started coronavirus related work to contribute to the global effort aimed at better understanding the virus and uncover its potential weaknesses. About the Young Scientist Keynote Award: This recognition honors a young scientist from the international protein science community who has contributed to scientific advancement and innovation in this field. Nominations were solicited from across academic and industry research groups in the fall of 2020, and the finalists were determined through the votes and input of our 15-person advisory panel.…
T
The Chain: Protein Engineering Podcast
1 Episode 31: The Role of Tags in Your Purification Toolbox w/ Dennis Karthaus 32:51
32:51 Play Later Play Later Lists Like Liked32:51
Play Later Play Later Lists Like LikedIn this episode we talk with Dennis Karthaus of IBA Lifesciences about his early science interests and pursing his PhD. His passion for marine biology eventually led him on a path to study biotechnology, where he now focuses on protein expression and purification. Specifically, tag-based purification that can help researchers increase lab productivity. But, as our guest explains, scientists should consider their specific bottlenecks and applications for the protein of interest, to determine if a tag is right for them.…
T
The Chain: Protein Engineering Podcast
1 Episode 30: Recombinant Methods to Generate Antibodies Against COVID-19 – Roundtable Discussion 1:00:04
1:00:04 Play Later Play Later Lists Like Liked1:00:04
Play Later Play Later Lists Like LikedIn a roundtable discussion, three experts bring perspectives on different methods for generating antibodies, including generating antibodies from naive libraries, patients, and immunizations. They discuss how the COVID-19 pandemic has highlighted the advantages of refocusing on infectious disease research. As well as the importance of having ready immune libraries and immunized mice, plus other approaches, ahead of any future infectious disease outbreak.…
T
The Chain: Protein Engineering Podcast
1 Episode 29: Efficient Chromatography Devices for Purification Requirements 32:50
32:50 Play Later Play Later Lists Like Liked32:50
Play Later Play Later Lists Like LikedThe purification requirements in the biopharmaceutical industry will be even more demanding in the coming years due to increased awareness of product-related impurities like oligomers, variants, positional isomers, and glycoforms. These impurities need to be separated from the final product. Dr. Raja Ghosh’s work focuses on the design and development of efficient chromatography devices that combine high-speed with high-resolution in separation. He speaks with Dr. David Wood of the Ohio State University about how the chromatography devices he is developing address these challenges.…
T
The Chain: Protein Engineering Podcast
1 Episode 28: Chasing Interleukin-2 from Academia to Industry w/ Willem Overwijk 30:33
30:33 Play Later Play Later Lists Like Liked30:33
Play Later Play Later Lists Like LikedOn this episode of The Chain, Dr. Willem Overwijk shares his personal experience of his recent transition from academia to industry, and the differences between the two. Dr. Overwijk moved to industry, in part, to follow his research interest in a specific molecule that he had been working on since graduate studies: interleukin-2. Thanks to advances in protein engineering, this once ultra-potent molecule now can be administered with lower toxicity while still being an effective cancer therapy. We discuss IL-2, plus the exciting future of protein engineering in immuno-oncology.…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.
Similar to The Chain: Protein Engineering Podcast
A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
This Week in Microbiology is a podcast about unseen life on Earth hosted by Vincent Racaniello and friends. Following in the path of his successful shows 'This Week in Virology' (TWiV) and 'This Week in Parasitism' (TWiP), Racaniello and guests produce an informal yet informative conversation about microbes which is accessible to everyone, no matter what their science background.
…
continue reading
Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Unexplainable takes listeners right up to the edge of what we know…and then keeps on going. The Unexplainable team — Noam Hassenfeld, Julia Longoria, Byrd Pinkerton, and Meradith Hoddinott — tackles scientific mysteries, unanswered questions, and everything we learn diving into the unknown. New episodes Mondays and Wednesdays.
…
continue reading
Unseeable forces control human behavior and shape our ideas, beliefs, and assumptions. Invisibilia—Latin for invisible things—fuses narrative storytelling with science that will make you see your own life differently.
…
continue reading
Going Wild with Dr. Rae Wynn Grant is a different kind of nature show about the human drama of saving animals. From a paleoanthropologist who hunts fossils in conflict zones to someone who helped save an endangered species while in prison, in season four we will hear from real-life heroes and nature advocates with widely different expertise and life experiences that led them to be champions for the natural world. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals i ...
…
continue reading
Deep in the back of your mind, you’ve always had the feeling that there’s something strange about reality. There is. Join Robert Lamb and Joe McCormick as they examine neurological quandaries, cosmic mysteries, evolutionary marvels and our transhuman future.
…
continue reading
All In The Mind is ABC RN's weekly podcast looking into the mental universe, the mind, brain and behaviour — everything from addiction to artificial intelligence.
…
continue reading
Science Friction's latest series is: Cooked. We dig into food science pickles. Why are studies showing that ice cream could be good for you? Do we really need as many electrolytes as the internet says? And why are people feeling good on the carnivore diet? Nutrition and food scientist Dr Emma Beckett takes us through what the evidence says about foods like meat, ice cream and potatoes — and unpicks why nutrition studies can be so conflicting and confusing. All six episodes of Cooked are avai ...
…
continue reading
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
